Tbo-Filgrastim Dosage
Medically reviewed by Drugs.com. Last updated on Jun 6, 2024.
Applies to the following strengths: 300 mcg/0.5 mL; 480 mcg/0.8 mL; 300 mcg/mL; 480 mcg/1.6 mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Neutropenia Associated with Chemotherapy
5 mcg/kg via subcutaneous injection once a day
- Duration of therapy: Treatment should continue until the expected neutrophil nadir is
Comments:
- Avoid administration during the period 24 hours before through 24 hours after the administration of cytotoxic chemotherapy.
- Monitor complete blood count (CBC) prior to chemotherapy and then 2 times a week until recovery.
Use: To reduce the duration of severe neutropenia in patients receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Usual Pediatric Dose for Neutropenia Associated with Chemotherapy
1 month and older: 5 mcg/kg via subcutaneous injection once a day
- Duration of therapy: Treatment should continue until the expected neutrophil nadir is
Comments:
- Avoid administration during the period 24 hours before through 24 hours after the administration of cytotoxic chemotherapy.
- Monitor CBC prior to chemotherapy and then 2 times a week until recovery.
Use: To reduce the duration of severe neutropenia in patients receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Renal Dose Adjustments
Data not available
Glomerulonephritis:
- Suspected glomerulonephritis: Evaluate for cause.
- Causality likely: Healthcare providers should consider dose reduction OR interruption of treatment.
Liver Dose Adjustments
Data not available
Dose Adjustments
Sickle cell crisis occurrence: Discontinue treatment.
Serious allergic reactions: Permanently discontinue treatment.
Suspected/confirmed splenic rupture, or aortitis, or acute respiratory distress syndrome (ARDS): Discontinue treatment.
Precautions
CONTRAINDICATIONS:
- Patients with a history of serious allergic reactions to filgrastim or pegfilgrastim products.
Safety and efficacy have not been established in patients younger than 1 month.
Consult WARNINGS section for dosing related precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug should not be injected into skin that is tender, red, bruised/hard, or has scars/stretch marks.
- Recommended injection sites include: The abdomen (except the 5 cm area surrounding the navel), middle of the thighs, upper outer areas of the buttocks, and/or the back of the upper arms. Injection sites should be changed every day.
- Discolored solutions or those containing particulates should not be used.
Storage requirements:
- Refrigerate at 2C to 8C and protect from light. Avoid shaking.
- Unused drug should be discarded.
General:
- Use of pre-filled syringes without safety needle guard devices should be restricted to properly trained patients/caregivers; healthcare providers should receive pre-filled syringes with safety needle guard devices.
- Some formulations are not made with natural rubber latex; the manufacturer product information should be consulted regarding excipients.
- Doses increasing the absolute neutrophil count (ANC) beyond 10,000/mm3 did not result in additional clinical benefit.
Monitoring:
- HEMATOLOGIC: CBC at least 2 times a week
Patient advice:
- Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
- Patients should be instructed to immediately report signs/symptoms of spleen enlargement/rupture, ARDS, glomerulonephritis, and/or allergic reactions to their healthcare provider.
More about tbo-filgrastim
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: colony stimulating factors
- En español
Patient resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.